Sander Bins

8PUBLICATIONS
11CO-AUTHORS
Cancer geneticsMolecular targetsToxicology (incl. clinical toxicology)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 16, 2023
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.

Mirjam de With, Leni van Doorn, Esmay Kloet

|Nov 10, 2022
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.

Leni van Doorn, Wesley J Visser, Daan C H van Dorst

|Jul 21, 2022
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

Mirjam de With, Gemma Brufau, Laila A van den Berg

|Jan 20, 2022
Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.

Wesley S van de Geer, Youri Hoogstrate, Kaspar Draaisma

|Jan 02, 2020
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.

Bodine P S Belderbos, Mirjam de With, Rajbir K Singh

|Dec 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.

Andrew Kl Goey, Mirjam de With, Bram C Agema

Pageof 2

Frequent Collaborators

2 joint publications

Mirjam de With

2 joint publications

Ron H J Mathijssen

1 joint publications

Andrew Kl Goey

1 joint publications

Wesley S van de Geer